|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Gupta N, Kupfer SS and Davis AM:
Colorectal Cancer Screening. JAMA. 321:2022–2023. 2019.
|
|
3
|
Kuipers EJ, Grady WM, Lieberman D,
Seufferlein T, Sung JJ, Boelens PG, van de Velde CJ and Watanabe T:
Colorectal cancer. Nat Rev Dis Primers. 1(15065)2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Al-Hajeili M, Marshall JL and Smaglo BG:
Neoadjuvant Treatment for Surgically Resectable Metastatic
Colorectal Cancer. Oncology (Williston Park). 30:10–16.
2016.PubMed/NCBI
|
|
5
|
Wang TY, Meng JH and Mai SC:
Electroacupuncture Treatment Conduced Before and After Surgery Is
Better in Promoting Reco-very of Gastrointestinal Function in
Colorectal Cancer Patients Undergoing Radical Resection. Zhen Ci
Yan Jiu. 43:797–800. 2018.(Iin Chinese). PubMed/NCBI View Article : Google Scholar
|
|
6
|
Drury A, Payne S and Brady AM: The cost of
survival: An exploration of colorectal cancer survivors'
experiences of pain. Acta Oncol. 56:205–211. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Wang D, Chen J, Chen H, Duan Z, Xu Q, Wei
M, Wang L and Zhong M: Leptin regulates proliferation and apoptosis
of colorectal carcinoma through PI3K/Akt/mTOR signalling pathway. J
Biosci. 37:91–101. 2012.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kocic B, Kitic D and Brankovic S: Dietary
flavonoid intake and colorectal cancer risk: Evidence from human
population studies. J BUON. 18:34–43. 2013.PubMed/NCBI
|
|
9
|
Jonker DJ, O'Callaghan CJ, Karapetis CS,
Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, et
al: Cetuximab for the treatment of colorectal cancer. N Engl J Med.
357:2040–2048. 2007.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Van Cutsem E, Köhne CH, Hitre E, Zaluski
J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G,
et al: Cetuximab and chemotherapy as initial treatment for
metastatic colorectal cancer. N Engl J Med. 360:1408–1417.
2009.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Hurwitz H, Fehrenbacher L, Novotny W,
Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S,
Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and
leucovorin for metastatic colorectal cancer. N Engl J Med.
350:2335–2342. 2004.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Dienstmann R, De Dosso S, Felip E and
Tabernero J: Drug development to overcome resistance to EGFR
inhibitors in lung and colorectal cancer. Mol Oncol. 6:15–26.
2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Van der Jeught K, Xu HC, Li YJ, Lu XB and
Ji G: Drug resistance and new therapies in colorectal cancer. World
J Gastroenterol. 24:3834–3848. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Frydoonfar HR, McGrath DR and Spigelman
AD: The variable effect on proliferation of a colon cancer cell
line by the citrus fruit flavonoid Naringenin. Colorectal Dis.
5:149–152. 2003.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Chen R, Qi QL, Wang MT and Li QY:
Therapeutic potential of naringin: An overview. Pharm Biol.
54:3203–3210. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Yoshinaga A, Kajiya N, Oishi K, Kamada Y,
Ikeda A, Chigwechokha PK, Kibe T, Kishida M, Kishida S, Komatsu M,
et al: NEU3 inhibitory effect of naringin suppresses cancer cell
growth by attenuation of EGFR signaling through GM3 ganglioside
accumulation. Eur J Pharmacol. 782:21–29. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Li H, Yang B, Huang J, Xiang T, Yin X, Wan
J, Luo F, Zhang L, Li H and Ren G: Naringin inhibits growth
potential of human triple-negative breast cancer cells by targeting
β-catenin signaling pathway. Toxicol Lett. 220:219–228.
2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Zeng L, Zhen Y, Chen Y, Zou L, Zhang Y, Hu
F, Feng J, Shen J and Wei B: Naringin inhibits growth and induces
apoptosis by a mechanism dependent on reduced activation of
NF-κB/COX-2-caspase-1 pathway in HeLa cervical cancer cells. Int J
Oncol. 45:1929–1936. 2014.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Ramesh E and Alshatwi AA: Naringin induces
death receptor and mitochondria-mediated apoptosis in human
cervical cancer (SiHa) cells. Food Chem Toxicol. 51:97–105.
2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Raha S, Yumnam S, Hong GE, Lee HJ,
Saralamma VV, Park HS, Heo JD, Lee SJ, Kim EH, Kim JA, et al:
Naringin induces autophagy-mediated growth inhibition by
downregulating the PI3K/Akt/mTOR cascade via activation of MAPK
pathways in AGS cancer cells. Int J Oncol. 47:1061–1069.
2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Morgensztern D and McLeod HL:
PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer
Drugs. 16:797–803. 2005.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Scartozzi M, Giampieri R, Maccaroni E,
Mandolesi A, Biagetti S, Alfonsi S, Giustini L, Loretelli C,
Faloppi L, Bittoni A, et al: Phosphorylated AKT and MAPK expression
in primary tumours and in corresponding metastases and clinical
outcome in colorectal cancer patients receiving
irinotecan-cetuximab. J Transl Med. 10(71)2012.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Oikonomou E and Pintzas A: Cancer genetics
of sporadic colorectal cancer: BRAF and PI3KCA mutations, their
impact on signaling and novel targeted therapies. Anticancer Res.
26A:1077–1084. 2006.PubMed/NCBI
|
|
24
|
Francipane MG and Lagasse E: mTOR pathway
in colorectal cancer: An update. Oncotarget. 5:49–66.
2014.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Kang S, Dong SM, Kim BR, Park MS, Trink B,
Byun HJ and Rho SB: Thioridazine induces apoptosis by targeting the
PI3K/Akt/mTOR pathway in cervical and endometrial cancer cells.
Apoptosis. 17:989–997. 2012.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Hamada K, Sasaki T, Koni PA, Natsui M,
Kishimoto H, Sasaki J, Yajima N, Horie Y, Hasegawa G, Naito M, et
al: The PTEN/PI3K pathway governs normal vascular development and
tumor angiogenesis. Genes Dev. 19:2054–2065. 2005.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Colakoglu T, Yildirim S, Kayaselcuk F,
Nursal TZ, Ezer A, Noyan T, Karakayali H and Haberal M:
Clinicopathological significance of PTEN loss and the
phosphoinositide 3-kinase/Akt pathway in sporadic colorectal
neoplasms: Is PTEN loss predictor of local recurrence? Am J Surg.
195:719–725. 2008.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Pandurangan AK: Potential targets for
prevention of colorectal cancer: A focus on PI3K/Akt/mTOR and Wnt
pathways. Asian Pac J Cancer Prev. 14:2201–2205. 2013.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Chen M, Peng W, Hu S and Deng J:
miR-126/VCAM-1 regulation by naringin suppresses cell growth of
human non-small cell lung cancer. Oncol Lett. 16:4754–4760.
2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Fang J, Ding M, Yang L, Liu LZ and Jiang
BH: PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis.
Cell Signal. 19:2487–2497. 2007.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Jiang QG, Li TY, Liu DN and Zhang HT:
PI3K/Akt pathway involving into apoptosis and invasion in human
colon cancer cells LoVo. Mol Biol Rep. 41:3359–3367.
2014.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Falcon BL, Barr S, Gokhale PC, Chou J,
Fogarty J, Depeille P, Miglarese M, Epstein DM and McDonald DM:
Reduced VEGF production, angiogenesis, and vascular regrowth
contribute to the antitumor properties of dual mTORC1/mTORC2
inhibitors. Cancer Res. 71:1573–1583. 2011.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Youle RJ and Strasser A: The BCL-2 protein
family: Opposing activities that mediate cell death. Nat Rev Mol
Cell Biol. 9:47–59. 2008.PubMed/NCBI View
Article : Google Scholar
|
|
34
|
Wang Y, Gu J, Hu L, Kong L, Wang T, Di M,
Li C and Gui S: miR-130a alleviates neuronal apoptosis and changes
in expression of Bcl-2/Bax and caspase-3 in cerebral infarction
rats through PTEN/PI3K/Akt signaling pathway. Exp Ther Med.
19:2119–2126. 2020.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Molton SA, Todd DE and Cook SJ: Selective
activation of the c-Jun N-terminal kinase (JNK) pathway fails to
elicit Bax activation or apoptosis unless the phosphoinositide
3'-kinase (PI3K) pathway is inhibited. Oncogene. 22:4690–4701.
2003.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Ma J, Sawai H, Ochi N, Matsuo Y, Xu D,
Yasuda A, Takahashi H, Wakasugi T and Takeyama H: PTEN regulates
angiogenesis through PI3K/Akt/VEGF signaling pathway in human
pancreatic cancer cells. Mol Cell Biochem. 331:161–171.
2009.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Primo L, di Blasio L, Roca C, Droetto S,
Piva R, Schaffhausen B and Bussolino F: Essential role of PDK1 in
regulating endothelial cell migration. J Cell Biol. 176:1035–1047.
2007.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Tian T, Nan KJ, Wang SH, Liang X, Lu CX,
Guo H, Wang WJ and Ruan ZP: PTEN regulates angiogenesis and VEGF
expression through phosphatase-dependent and -independent
mechanisms in HepG2 cells. Carcinogenesis. 31:1211–1219.
2010.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Erdogan S, Doganlar O, Doganlar ZB and
Turkekul K: Naringin sensitizes human prostate cancer cells to
paclitaxel therapy. Prostate Int. 6:126–135. 2018.PubMed/NCBI View Article : Google Scholar
|
